HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published All Versions of this Article: JOE-08-0113v1 198/2/367    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Holmes, A. G Articles by Febbraio, M. A PubMed PubMed Citation Articles by Holmes, A. G Articles by Febbraio, M. A

¹ Diabetes and Metabolism Division, Cellular and Molecular Metabolism Laboratory, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria 8008, Australia² School of Medical Sciences, RMIT University, Bundoora, Victoria 3083, Australia³ St Vincent's Institute and Department of Medicine, The University of Melbourne, Fitzroy, Victoria 3065, Australia⁴ CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville, Victoria 3052, Australia⁵ Department of Physiology, Monash University, Clayton, Victoria 3800, Australia

(Correspondence should be addressed to M A Febbraio; Email: mark.febbraio{at}baker.edu.au)

(J L Mesa is currently at the Medical Research Centre, Epidemiology Unit, Cambridge, UK)

^* (A G Holmes and J L Mesa contributed equally to this work)

Chronic elevations in interleukin (IL)-6 have been associated with insulin resistance, but acute IL-6 administration can enhance insulin sensitivity. Our aim was to exogenously administer IL-6 to rats to elicit either chronic or repeated acute elevations in systemic IL-6. We hypothesized that a continuous elevation of IL-6 would inhibit glucose tolerance and insulin sensitivity while acute intermittent elevations would improve it. Male Wistar rats were treated for 14d with recombinant human IL-6 (2.4 µg/day) or saline administered either by miniosmotic pump (continuous IL-6) or via twice-daily injection (intermittent IL-6). Glucose and insulin tolerance tests were performed following 14-d treatment and 24 h later rats were administered a bolus of insulin (150 mU/g) or saline intraperitoneally. Approximately, 10 min after insulin injection soleus, gastrocnemius and liver were excised and rapidly frozen in liquid nitrogen for subsequent metabolic measures. Irrespective of the mode of delivery, IL-6 treatment increased basal insulin sensitivity, as measured by the homeostatic model assessment of insulin resistance, and enhanced glucose clearance during an i.p. glucose tolerance test. IL-6 increased circulating fatty acids, but did not increase triglyceride accumulation in either skeletal muscle or liver, while it increased the protein expression of both PPAR and UCP2 in skeletal muscle, suggesting that IL-6 can enhance fat oxidation via mitochondrial uncoupling. These data demonstrate that, irrespective of the mode of delivery, IL-6 administration over 2 weeks enhances glucose tolerance. Our results do not support the notion that prolonged chronically elevated IL-6 impairs insulin action in vivo.